Digitalis-induced increase in aortic regurgitation and the contrasting effect of glucagon in the sedated dog.
The hemodynamic and phasic ascending aortic flow changes induced by acetylstrophanthidin and glucagon were studied in closed-chest sedated dogs with aortic regurgitation. While the positive inotropic effect of both agents was reflected in an increase in peak rate of rise of left ventricular pressure, acetylstrophanthidin increased aortic regurgitation, while glucagon decreased it. With the former, left ventricular end-diastolic pressure rose from 20+/-6 to 27+/-6 mm Hg (P < 0.005), but fell from 18+/-4 to 11+/-3 mm Hg (P < 0.001) with glucagon. Acetylstrophanthidin increased systemic vascular resistance, aortic diastolic pressure, and diastolic regurgitant flow rate, and, heart rate and the duration of regurgitation per beat and per minute being unchanged, regurgitant flow per beat increased 32+/-15% (P < 0.001). Glucagon decreased regurgitant flow per beat 27+/-14% (P < 0.001) because of abbreviation of diastole associated with tachycardia, and because of reduction in regurgitant flow rate. Despite tachycardia, the duration of regurgitation per minute was unchanged, and the small fall in regurgitant blood flow per minute was not significant, but this pertained in the face of 47% increase in effective cardiac output (P < 0.001). In contrast, acetylstrophanthidin increased regurgitant flow per minute 28+/-14% (P < 0.001) without change in effective cardiac output. The increase in cardiac contractility, tachycardia, and systemic vasodilatation induced by glucagon preferentially enhanced forward blood flow, which led to reduction in left ventricular volume overload, while it increased cardiac output. Contrarily, acetylstrophanthidin increased aortic regurgitation and, despite its inotropic effect, increased left ventricular volume overload without an increase in cardiac output.
D000818:Animals; D001022:Aortic Valve Insufficiency / Q000139:chemically induced* / Q000188:drug therapy; D001794:Blood Pressure / Q000187:drug effects; D002297:Cardanolides / Q000494:pharmacology; D002302:Cardiac Output / Q000187:drug effects; D004106:Dilatation; D004285:Dogs; D004562:Electrocardiography; D005934:Glucagon / Q000494:pharmacology* / Q000627:therapeutic use; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects; D010042:Ouabain / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D013268:Stimulation, Chemical; D013328:Strophanthins / Q000009:adverse effects*; D014655:Vascular Resistance / Q000187:drug effects
D002297:Cardanolides; D013328:Strophanthins; D010042:Ouabain; D005934:Glucagon